CFH in ultracentrifugation pellet and plasma of lung cancer patients.
2021
Bild
Zugriff:
EVs were isolated from plasma by ultracentrifugation. Equal volumes of ultracentrifugation pellet and original plasma from each patient were subjected to western blot analysis. The blots were each probed with GT103 followed by an anti-mouse IgG-HRP secondary reagent (to prevent background binding of a human secondary reagent to human IgG in the samples). Top blot: The pellet from 5 early stage (1–5) and 5 late stage (6–10) patients. The last lane contains 20 ng purified human CFH (Complement Technology, Inc.) Bottom blot: Plasma from the same patients. The pellet and plasma from two control patients with no cancer (nc) are also included on the blot. Shown are results from a subset of 10 lung cancer patients of a total of 19 analyzed; only one early stage patient had a detectible CFH band in EVs. (See S2 Fig for 9 additional human samples, including the early stage patient with CFH-containing EVs).
Titel: |
CFH in ultracentrifugation pellet and plasma of lung cancer patients.
|
---|---|
Autor/in / Beteiligte Person: | Ryan T. Bushey (4179223) ; Elizabeth B. Gottlin (4179220) ; Michael J. Campa (2356159) ; Edward F. Patz Jr. (4179217) |
Link: | |
Veröffentlichung: | 2021 |
Medientyp: | Bild |
DOI: | 10.1371/journal.pone.0252577.g003 |
Schlagwort: |
|
Sonstiges: |
|